ProThera Biologics, Inc.
ProThera Biologics is a Rhode Island-based bio-therapeutics Company pioneering the development of innovative products based on Inter-alpha Inhibitor Proteins (IAIP).
The Company was founded in 2002 to focus on the critical role and commercial potential of IAIP for treating acute, life-threatening inflammatory diseases.
IAIP are a family of naturally occurring proteins found in high concentration in human plasma and play an important role in the regulation of host immune response.
Led by Yow-Pin Lim, MD/PhD and Denice Spero, PhD, the company is backed by the Slater Technology Fund and has received continuous funding from the National Institutes of Health with Phase I and II Small Business Innovation Research (SBIR) grants over the past 10 years.
ProThera has elucidated the efficacy of IAIP in multiple models and is pursuing the usage of IAIP to fight systemic inflammation across multiple indication areas.
The Company has developed a novel process to purify Inter-alpha Inhibitor Proteins from source material and has designated ProMetic Life Sciences, Inc. to be its manufacturing and supply partner.